DGAP-News

Sangui BioTech International Inc.: Revenues of USD 36,000 in the first half-year; Granulox license income increased by 33%

DGAP-News: Sangui BioTech International Inc. / Key word(s): Development of
Sales
Sangui BioTech International Inc.: Revenues of USD 36,000 in the first
half-year; Granulox license income increased by 33%

12.01.2017 / 10:50
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------




Sangui BioTech:
- Revenues of USD 36,000 in the first half-year;
- Granulox license income increased by 33%.

Witten, January 12, 2017,
According to preliminary unaudited figures, Sangui BioTech International
Inc. achieved revenues in the amount of approximately USD 36,000 from
license fees in the first half year of fiscal 2017 (as of December 31,
2016). Due to increased revenues of the wound spray Granulox, the resulting
licensing income in the first half year increased by 33% compared to the
same period of the previous year. After a cautious first quarter,
especially a strong end-of-year business was responsible for this
development. Particularly pleasing was the fact that the increase in
revenues was caused by expanding business with existing partners, e.g.
Silanes in Mexico, and not by one-time effects with new contract partners.

"As in previous years, we were able to look back on a strong year-end
business. The development in Mexico is more than pleasing. The fact that
Granulox's foreign revenues have more than doubled over the past 12 months
shows that the business is developing on an increasingly broader basis.
This effect will be intensified by the planned activities of our partners
in Southeast Asia, Russia and the UK, among others. Our business is also
subject to seasonal fluctuations. As a result, revenues of the following
quarter are not expected to reach that of the quarter under report. For the
full year 2017, however, we are counting on the further growth in total
revenues for Granulox, "explains Michael Sander, Managing Director of
SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide
distribution rights for the wound spray Granulox.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such forward-
looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.


---------------------------------------------------------------------------

12.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

535835 12.01.2017